A Practical Guide to Achieving and Maintaining Global Oversight and Ensuring End-to-End Pharmacovigilance
Pharmacovigilance leaders must be both strategic and practical in their approach to achieving more with less, making wise use of existing resources.
This white paper outlines the practical steps that pharmacovigilance leaders should take in order to achieve and maintain global oversight of their pharmacovigilance process. This is especially important in the light of regulatory changes that have expanded the scope of work required by those responsible for monitoring drug safety.
End-to-end pharmacovigilance can greatly benefit from modern research technology, not only in terms of driving efficiencies but also in terms of monitoring and measuring performance, identifying operational risks and improving signal detection.
Learn about the role that technology can play, focusing on solutions for literature monitoring.
Read the white paper.
To access the complimentary white paper 'A Practical Guide to Achieving and Maintaining Global Oversight and Ensuring End-to-End Pharmacovigilance', please fill in the form below.
Elsevier's R&D Solutions for Pharmacovigilance
Promote efficiency and organizational compliance by centralizing the discovery of adverse event information and automating information monitoring and triage in a scalable environment.
Learn more about QUOSA PV
Contact a QUOSA PV expert
Make more informed drug development decisions on safety and efficacy, risk assessments and mitigation, and study designs by providing researchers with searchable FDA/EMA drug approval documents and comparative drug safety data.
Learn more about PharmaPendium
Contact a PharmaPendium expert
Innovation and Performance: What's Data Got to Do With It?
Pharmaceutical companies must uphold patient safety and manage pharmacovigilance regulatory compliance risks. How are industry leaders driving business performance amidst big data? What are the common challenges and bottlenecks?
Professional Services Case Study: Compliant Monitoring of Adverse Events
A review of how Elsevier's R&D Solution Professional Services helped a pharmaceutical company become more compliant with literature screening requirements.